Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 19.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,516 shares of the medical research company’s stock after purchasing an additional 10,164 shares during the period. IFM Investors Pty Ltd’s holdings in Thermo Fisher Scientific were worth $36,334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $2,784,029,000. BlackRock Inc. increased its stake in Thermo Fisher Scientific by 3.8% in the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after purchasing an additional 1,143,333 shares in the last quarter. Marshall Wace LLP increased its stake in Thermo Fisher Scientific by 146.4% in the 4th quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company’s stock valued at $696,497,000 after purchasing an additional 620,291 shares in the last quarter. State Street Corp increased its stake in Thermo Fisher Scientific by 3.4% in the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock valued at $10,828,875,000 after purchasing an additional 529,712 shares in the last quarter. Finally, KBC Group NV increased its stake in Thermo Fisher Scientific by 52.9% in the 4th quarter. KBC Group NV now owns 697,313 shares of the medical research company’s stock valued at $465,276,000 after purchasing an additional 241,183 shares in the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 17,150 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $548.30, for a total value of $9,403,345.00. Following the transaction, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at $8,640,111.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Michel Lagarde sold 17,150 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following the sale, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at $8,640,111.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 2,181 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $562.46, for a total value of $1,226,725.26. Following the sale, the chief executive officer now directly owns 183,373 shares in the company, valued at $103,139,977.58. The disclosure for this sale can be found here. Insiders have sold 32,361 shares of company stock valued at $17,992,541 over the last three months. 0.43% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. Wells Fargo & Company cut Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $605.00 to $525.00 in a report on Monday, April 25th. Barclays lowered their target price on Thermo Fisher Scientific from $675.00 to $630.00 and set an “overweight” rating on the stock in a report on Wednesday, July 13th. Morgan Stanley increased their target price on Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a report on Friday. Finally, SVB Leerink increased their target price on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $652.79.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $598.41 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $497.83 and a twelve month high of $672.34. The stock has a market capitalization of $234.25 billion, a P/E ratio of 31.20, a PEG ratio of 1.93 and a beta of 0.82. The company has a current ratio of 1.56, a quick ratio of 1.10 and a debt-to-equity ratio of 0.77. The business’s fifty day moving average price is $545.16 and its 200 day moving average price is $557.45.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, beating analysts’ consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $9.95 billion. During the same quarter last year, the firm earned $5.60 earnings per share. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.63 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be given a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 0.20%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.26%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Want More Great Investing Ideas?

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.